We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+25.15%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$8.17B
AUM Growth
+$2.55B
Cap. Flow
+$12.3M
Cap. Flow %
0.15%
Top 10 Hldgs %
61.52%
Holding
432
New
171
Increased
73
Reduced
69
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$36.1M
3
SNY icon
Sanofi
SNY
+$34.1M
4
CYTK icon
Cytokinetics
CYTK
+$31.4M
5
WAT icon
Waters Corp
WAT
+$25.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$147M
2
PTCT icon
PTC Therapeutics
PTCT
+$72.4M
3
IMVT icon
Immunovant
IMVT
+$55.7M
4
DDOG icon
Datadog
DDOG
+$31.8M
5
AVNS
Avanos Medical
AVNS
+$28M

Sector Composition

Rank Sector Weight
1 Miscellaneous 55.89%
2 Healthcare 30.09%
3 Technology 6.58%
4 Consumer Discretionary 3.42%
5 Communication Services 1.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALAB icon
151
Astera Labs
ALAB
$53.8B
$3.05M 0.04%
+6,323
New +$1.68M
MPWR icon
152
Monolithic Power Systems
MPWR
$60.1B
$3.02M 0.04%
+2,186
New +$3.28M
KYNB
153
Kyntra Bio
KYNB
$34.6M
$3.02M 0.04%
400,000
– –
ENTG icon
154
Entegris
ENTG
$21.2B
$3.01M 0.04%
+16,737
New +$2.41M
RRX icon
155
Regal Rexnord
RRX
$10.8B
$2.97M 0.04%
+12,461
New +$2.6M
REPL icon
156
Replimune Group
REPL
$1.42B
$2.92M 0.04%
+264,000
New +$1.61M
BGS icon
157
B&G Foods
BGS
$267M
$2.67M 0.03%
+672,000
New +$3.12M
VRCA icon
158
Verrica Pharmaceuticals
VRCA
$91M
$2.61M 0.03%
426,304
-91,877
-18% -$573K
GLW icon
159
Corning
GLW
$133B
$2.58M 0.03%
10,112
-20,645
-67% -$3.76M
CNDT icon
160
Conduent
CNDT
$302M
$2.47M 0.03%
1,692,000
+56,000
+3% +$87K
INUV icon
161
Inuvo
INUV
$10.7M
$2.04M 0.03%
+1,622,307
New +$2.73M
ABT icon
162
Abbott
ABT
$187B
$2.03M 0.02%
+22,381
New +$2.04M
ASML icon
163
ASML
ASML
$659B
$2.02M 0.02%
1,014
-1,286
-56% -$2.05M
KLAC icon
164
KLA
KLAC
$242B
$1.98M 0.02%
+6,568
New +$1.3M
COHR icon
165
Coherent
COHR
$55.2B
$1.9M 0.02%
+4,814
New +$1.7M
SG icon
166
Sweetgreen
SG
$814M
$1.85M 0.02%
+210,526
New +$1.61M
BROS icon
167
Dutch Bros
BROS
$6.43B
$1.85M 0.02%
25,772
+21,394
+489% +$1.23M
SBH icon
168
Sally Beauty Holdings
SBH
$1.56B
$1.78M 0.02%
+126,227
New +$1.7M
LFST icon
169
Lifestance Health
LFST
$4.86B
$1.78M 0.02%
+165,885
New +$1.28M
CRI icon
170
Carter's
CRI
$1.23B
$1.77M 0.02%
+43,051
New +$1.63M
AVTR icon
171
Avantor
AVTR
$10.1B
$1.68M 0.02%
+170,000
New +$1.46M
CTRN icon
172
Citi Trends
CTRN
$593M
$1.66M 0.02%
+28,748
New +$1.38M
A icon
173
Agilent Technologies
A
$42.5B
$1.59M 0.02%
+11,982
New +$1.46M
ULTA icon
174
Ulta Beauty
ULTA
$24.1B
$1.57M 0.02%
3,486
-9,250
-73% -$4.7M
ODD icon
175
ODDITY Tech
ODD
$634M
$1.5M 0.02%
+99,385
New +$1.33M
5 6
7
8 9

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Armistice Capital held 432 positions worth $8.17B, up 45% from $5.62B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Armistice Capital's Q2 2026 filing shows 171 new, 73 increased, 69 reduced and 99 closed positions. Its largest new stake was Waters Corp: 75,004 shares worth $28.1M. The largest sale was Travere Therapeutics, an estimated $147M.

By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 46% a quarter earlier, followed by Healthcare and Technology.

  • Armistice Capital's largest Q2 2026 buy was Waters Corp: 75,004 shares worth $28.1M.
  • Armistice Capital added most to Regeneron Pharmaceuticals in Q2 2026, an estimated $36.5M increase.
  • Armistice Capital's biggest Q2 2026 reduction was Travere Therapeutics, cutting an estimated $147M.
  • Armistice Capital fully exited Avanos Medical in Q2 2026, selling an estimated $28M.
  • Armistice Capital's ten largest holdings make up 62% of its $8.17B portfolio in Q2 2026.
  • Armistice Capital opened 171 new positions and closed 99 in Q2 2026.
  • Armistice Capital's portfolio value rose 45% quarter-over-quarter to $8.17B.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.